Axonics Modulation Technologies’ (AXNX) “Buy” Rating Reiterated at Wells Fargo & Co

Share on StockTwits

Wells Fargo & Co reissued their buy rating on shares of Axonics Modulation Technologies (NASDAQ:AXNX) in a research report sent to investors on Friday, AnalystRatings.com reports.

AXNX has been the topic of a number of other reports. Svb Leerink began coverage on Axonics Modulation Technologies in a report on Tuesday, September 17th. They set an outperform rating and a $45.00 target price on the stock. Bank of America raised their price target on Axonics Modulation Technologies from $35.00 to $40.00 and gave the company a buy rating in a report on Tuesday, September 10th. Zacks Investment Research cut shares of Axonics Modulation Technologies from a buy rating to a hold rating in a research report on Wednesday, November 13th. ValuEngine upgraded shares of Axonics Modulation Technologies from a sell rating to a hold rating in a report on Wednesday, November 6th. Finally, Leerink Swann initiated coverage on shares of Axonics Modulation Technologies in a research report on Tuesday, September 17th. They issued an outperform rating and a $45.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Axonics Modulation Technologies currently has an average rating of Buy and an average price target of $40.22.

Axonics Modulation Technologies stock opened at $25.53 on Friday. The stock has a 50-day simple moving average of $23.23 and a 200 day simple moving average of $30.84. The stock has a market capitalization of $730.23 million, a P/E ratio of -5.50 and a beta of -1.74. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.76 and a current ratio of 7.58. Axonics Modulation Technologies has a 52 week low of $13.00 and a 52 week high of $43.37.

Axonics Modulation Technologies (NASDAQ:AXNX) last released its quarterly earnings data on Thursday, November 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.14). Axonics Modulation Technologies had a negative net margin of 1,530.43% and a negative return on equity of 55.57%. The business had revenue of $1.31 million during the quarter, compared to the consensus estimate of $1.45 million. The business’s revenue for the quarter was up 555.0% compared to the same quarter last year. Research analysts forecast that Axonics Modulation Technologies will post -2.79 earnings per share for the current year.

In related news, CEO Raymond W. Cohen sold 75,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $20.74, for a total value of $1,555,500.00. Following the completion of the sale, the chief executive officer now directly owns 608,391 shares in the company, valued at $12,618,029.34. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Rinda Sama sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.61, for a total value of $133,050.00. In the last three months, insiders sold 760,000 shares of company stock valued at $15,878,450. 35.99% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of AXNX. BNP Paribas Arbitrage SA acquired a new position in Axonics Modulation Technologies in the second quarter valued at about $35,000. Partner Investment Management L.P. bought a new position in shares of Axonics Modulation Technologies in the 3rd quarter valued at $52,000. Bank of Montreal Can lifted its position in shares of Axonics Modulation Technologies by 963.7% during the 2nd quarter. Bank of Montreal Can now owns 1,436 shares of the company’s stock worth $58,000 after buying an additional 1,301 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in Axonics Modulation Technologies by 84.0% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,300 shares of the company’s stock valued at $94,000 after buying an additional 1,050 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY bought a new position in Axonics Modulation Technologies in the third quarter valued at about $145,000. Institutional investors own 33.99% of the company’s stock.

About Axonics Modulation Technologies

Axonics Modulation Technologies, Inc, a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention.

Featured Article: Day Trading

Analyst Recommendations for Axonics Modulation Technologies (NASDAQ:AXNX)

Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Arrowhead Pharmaceuticals Inc  Shares Acquired by Nisa Investment Advisors LLC
Arrowhead Pharmaceuticals Inc Shares Acquired by Nisa Investment Advisors LLC
Nisa Investment Advisors LLC Sells 18,900 Shares of Waddell & Reed Financial, Inc.
Nisa Investment Advisors LLC Sells 18,900 Shares of Waddell & Reed Financial, Inc.
Nisa Investment Advisors LLC Increases Holdings in Unitil Co.
Nisa Investment Advisors LLC Increases Holdings in Unitil Co.
Nisa Investment Advisors LLC Grows Position in Generac Holdings Inc.
Nisa Investment Advisors LLC Grows Position in Generac Holdings Inc.
Nisa Investment Advisors LLC Lowers Stock Holdings in Easterly Government Properties Inc
Nisa Investment Advisors LLC Lowers Stock Holdings in Easterly Government Properties Inc
Nisa Investment Advisors LLC Buys 300 Shares of Horizon Therapeutics PLC
Nisa Investment Advisors LLC Buys 300 Shares of Horizon Therapeutics PLC


© 2006-2020 Ticker Report